Paul Frewer

4.8k citations
38 papers · 3.6k indexed · 4 hit papers · h-index 19

Paul Frewer

37 papers receiving 3.5k citations

Hit Papers

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lu...2008202620142020201520082020202250010001.5k

Peers

Paul Frewer
Comparison fields: 5 of 100
  • Pulmonary and Respiratory Medicine 2.2k
  • Oncology 1.7k
  • Molecular Biology 1.3k
  • Cancer Research 579
  • Surgery 442
Replace Yingyong Hou with:
Yingyong Hou China
Roland Penzel Germany
Tamara L. Lotan United States
Shinji Takeuchi Japan
Hiroyasu Kaneda Japan
Elizabeth R. Lawlor United States
David F. Schaeffer Canada
Leander Van Neste United States
Sanna-Maria Käkönen Finland
Andres Jan Schrader Germany
Paul Frewer relative to Yingyong Hou China Yingyong Hou's profile →
Citations per field
00.5×2.7×
Yingyong Hou · 1×
Citations per year

Countries citing papers authored by Paul Frewer

Since Specialization
Citations

This map shows the geographic impact of Paul Frewer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Frewer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Frewer more than expected).

Fields of papers citing papers by Paul Frewer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Frewer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Frewer. The network helps show where Paul Frewer may publish in the future.

Co-authorship network of co-authors of Paul Frewer

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Frewer. A scholar is included among the top collaborators of Paul Frewer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Frewer. Paul Frewer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTONbreakdown →
95
2 1
3 71
4
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studybreakdown →
295
5 6
6 115
7 149
8 105
9 15
10
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancerbreakdown →
1585
11 40
12 126
13 16
14
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumabbreakdown →
403
15 145
16 52
17 34
18 37
19 1
20 4

About Paul Frewer

Paul Frewer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, having authored 38 papers that have together received 3.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), DNA Repair Mechanisms (6 papers) and Lung Cancer Research Studies (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.2k citations), Oncology (1.7k citations) and Cancer Research (579 citations). Paul Frewer has collaborated with scholars based in United Kingdom, United States and South Korea. Frequent co-authors include Mireille Cantarini, Myung‐Ju Ahn, James Chih‐Hsin Yang, Wu‐Chou Su, Sang-We Kim, Paul A. Dickinson, Pasi A. Jänne, Suresh S. Ramalingam, Leora Horn and Yuichiro Ohe. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026